Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug

Apnimed isn’t resting on its laurels. A year after its series B financing, the clinical-stage pharmaceutical has closed a $62.5 million series C round designed to push its obstructive sleep apnea (OSA) drug into phase 3 trials.